Delving into the Latest Updates on Recombinant chimeric anti-EGFR monoclonal antibody (Xinweishengke Bio) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

卫拓

Target

EGFR

Action

antagonists

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Advanced Malignant Solid NeoplasmEsophageal CarcinomaStomach Cancer

Inactive Indication-

Originator Organization

Zhejiang Xinweishengke Biotechnology Co., Ltd.

Active Organization

Zhejiang Xinweishengke Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary purpose: Observe the safety and tolerability of BK011 in the treatment of patients with advanced solid tumors; Determine the maximum tolerated dose (MTD) of BK011 and the appropriate recommended dose (RD) for subsequent studies; Secondary purpose: Evaluate the pharmacokinetic characteristics and immunogenicity of BK011; Preliminary evaluation of the effectiveness of BK011 in the treatment of patients with advanced solid tumors;

Start Date18 May 2022

Sponsor / Collaborator

Zhejiang Xinweishengke Biotechnology Co., Ltd.

100 Clinical Results associated with Recombinant chimeric anti-EGFR monoclonal antibody (Xinweishengke Bio)

Login to view more data

100 Translational Medicine associated with Recombinant chimeric anti-EGFR monoclonal antibody (Xinweishengke Bio)

Login to view more data

100 Patents (Medical) associated with Recombinant chimeric anti-EGFR monoclonal antibody (Xinweishengke Bio)

Login to view more data

100 Deals associated with Recombinant chimeric anti-EGFR monoclonal antibody (Xinweishengke Bio)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Zhejiang Xinweishengke Biotechnology Co., Ltd.	18 May 2022
Esophageal Carcinoma	Phase 1	China	Zhejiang Xinweishengke Biotechnology Co., Ltd.	18 May 2022
Stomach Cancer	Phase 1	China	Zhejiang Xinweishengke Biotechnology Co., Ltd.	18 May 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data